Comparative Pharmacology
Head-to-head clinical analysis: EPINEPHRINE BITARTRATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINEPHRINE BITARTRATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Alpha-adrenergic effects increase peripheral vascular resistance and blood pressure. Beta1-adrenergic effects increase heart rate and contractility. Beta2-adrenergic effects cause bronchodilation and vasodilation in skeletal muscle.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion: 0.1 to 1 mcg/kg/min, titrated to effect. Intravenous bolus: 1 mg every 3-5 minutes as needed for cardiac arrest. Intramuscular: 0.3 to 0.5 mg (1:1000 solution) for anaphylaxis, repeat every 5-15 minutes if necessary.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life: ~2 minutes following intravenous administration; clinical context: ultrashort duration necessitates continuous infusion or repeated boluses for sustained effect.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Primarily renal; 90% as metabolites (metanephrine, vanillylmandelic acid) and unchanged drug; biliary/fecal <5%.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."